Upas Tree

Antiaris toxicaria contains potent cardiac glycosides (including antiarosides A–I and malayoside) that inhibit Na⁺/K⁺-ATPase, and hydroxycinnamates and flavonoids in leaf fractions that induce dose-dependent apoptosis in cancer cell lines. In preclinical in vitro studies, the hydro-alcoholic aqueous leaf fraction produced greater than 50% cell death at 100 µg/mL across MCF-7, THP-1, SW620, and AsPC-1 cancer lines, with EC50 values ranging from 61 to 100 µg/mL, though no human clinical data exist to support therapeutic application.

Origin & History

Antiaris toxicaria Lesch. is a large tropical tree native to a broad range spanning West Africa through South and Southeast Asia to the Pacific Islands, including Papua New Guinea, Indonesia, Malaysia, and the Philippines. It thrives in lowland tropical rainforests and mixed dipterocarp forest environments, often reaching heights of 25–40 meters, and is adapted to humid, high-rainfall equatorial climates with well-drained lateritic soils. The tree has been recognized across its range by indigenous communities for centuries primarily for the extreme toxicity of its latex, which was historically used as arrow poison, though seeds, bark, and leaves have also been employed in localized folk medicine traditions.

Historical & Cultural Context

Antiaris toxicaria has been documented across its range for centuries primarily as a source of the infamous 'upas' arrow poison, derived from the toxic latex of the trunk, which was used by indigenous communities in Java, Borneo, Malaysia, and parts of Africa to tip blowgun darts and arrows for hunting and warfare, with historical accounts reaching European literature as early as the 18th century. In Papua New Guinea, specifically among the Siwai and Buin peoples of Bougainville, heated seeds have been used orally as a folk remedy for small external or superficial growths, representing a distinct and localized therapeutic application that diverges from the predominant toxicological use of the species. In Indonesian and broader Asian traditional medicine, the bark, leaves, and latex have also been employed for various biological effects including treatment of skin conditions and as a general medicinal plant, though detailed ethnobotanical preparation recipes are not systematically recorded in the peer-reviewed literature available. The species was formally described by Leschenault de la Tour (Lesch.) in the early 19th century, and systematic phytochemical investigation of its cardiac glycoside content began appearing in the scientific literature from the 1980s onward, with comprehensive phenolic profiling emerging only from approximately 2013 onward.

Health Benefits

- **Cytotoxic and Pro-apoptotic Activity**: Hydro-alcoholic aqueous leaf fractions induce programmed cell death in breast (MCF-7), leukemia (THP-1), colon (SW620), and pancreatic (AsPC-1) cancer cell lines via annexin-V-confirmed apoptosis, with EC50 values between 61–100 µg/mL and near-complete cytotoxicity (0.1% viability) at 200 µg/mL.
- **Cardiotonic Effects**: Cardiac glycosides isolated from trunk bark, particularly antiarosides A–I and malayoside, exert positive inotropic effects on guinea pig atrial tissue through Na⁺/K⁺-ATPase inhibition in a manner comparable in potency to the reference compound ouabain, suggesting theoretical utility in cardiac contractility modulation under strictly controlled conditions.
- **Antioxidant Capacity**: Methanolic leaf extracts demonstrate dose-dependent free radical scavenging activity, achieving 80–100% DPPH inhibition at higher microgram-per-milliliter concentrations, attributed primarily to the presence of hydroxycinnamate derivatives and the flavonoid rutin isomers first detected in this species via UPLC-DAD-QTOF-MS/MS analysis.
- **Antibacterial Properties**: Crude extracts have shown inhibitory activity against six bacterial species in preliminary screening studies, with phytochemical surveys detecting 10 of 17 tested compound groups, including tannins, saponins, and alkaloids, suggesting broad-spectrum bacteriostatic potential requiring further mechanistic characterization.
- **Cytostatic Potential at Sub-lethal Concentrations**: At concentrations as low as 12.5 µg/mL, leaf fractions produce a three-fold reduction in cancer cell proliferation without inducing outright cytotoxicity, indicating a cytostatic effect that may be relevant to understanding dose-response relationships in future preclinical cancer models.
- **Anti-inflammatory Potential (Inferred)**: The presence of hydroxycinnamate phenolics and rutin isomers—compound classes well-established in other plant species as NF-κB pathway modulators and COX inhibitors—provides a phytochemical basis for hypothesizing anti-inflammatory activity, though no direct anti-inflammatory assays on Antiaris toxicaria extracts have been published as of available literature.

How It Works

The cardiac glycosides of Antiaris toxicaria, including antiarosides A–I and antiarotoxinin A, act as competitive inhibitors of the alpha-subunit of Na⁺/K⁺-ATPase on cardiomyocyte plasma membranes, increasing intracellular sodium concentration and secondarily elevating cytosolic calcium via the Na⁺/Ca²⁺ exchanger, which produces positive inotropy but at toxic doses leads to arrhythmogenesis. The hydro-alcoholic aqueous leaf fraction, rich in hydroxycinnamates (compounds 2–10, 15–16) and a rutin isomer (compound 12), triggers intrinsic apoptotic pathways in cancer cell lines, as evidenced by annexin-V phosphatidylserine externalization, suggesting activation of caspase cascades and mitochondrial membrane depolarization, though the precise upstream initiators have not been molecularly characterized in this species. Antioxidant activity is mechanistically attributable to the electron-donating capacity of phenolic hydroxyl groups in hydroxycinnamate and flavonoid structures, which quench reactive oxygen species via hydrogen atom transfer and single-electron transfer mechanisms. The antibacterial effects are broadly hypothesized to result from membrane disruption by saponins and inhibition of bacterial cell wall biosynthesis by tannin-protein complexes, consistent with the detected phytochemical profile, but species-specific target identification remains unreported.

Scientific Research

The available evidence base for Antiaris toxicaria is entirely preclinical, comprising in vitro cell-line studies, ex vivo organ bath preparations, and phytochemical characterization analyses, with no peer-reviewed human clinical trials identified in the literature as of the most recent available sources. A key in vitro study characterized the hydro-alcoholic aqueous leaf fraction using UPLC-DAD-QTOF-MS/MS, reporting EC50 apoptotic values of 63.5 ± 1.8 µg/mL in MCF-7 cells and 64.6 ± 13.7 µg/mL cytostatic values, across four cancer cell lines with replicated but numerically unspecified sample sizes, marking the first detection of hydroxycinnamates and rutin isomers in this species. Ex vivo cardiotonic studies on isolated guinea pig atria confirmed Na⁺/K⁺-ATPase-mediated positive inotropic effects of bark-derived cardiac glycosides comparable to ouabain, though no safety index or therapeutic ratio data in whole-animal models were published. Phytochemical screening studies, including those employing petroleum ether (0.89% yield), chloroform (2.91% yield), and methanolic extraction, corroborate antioxidant and antibacterial activities but lack standardization, dose-response rigor, and bioavailability assessment, placing the overall evidence quality at an early exploratory stage.

Clinical Summary

No human clinical trials—Phase I, II, or III—have been conducted on Antiaris toxicaria extracts, seeds, or isolated compounds in any recognized medical or supplementation context. All outcome data derive from in vitro cancer cell cytotoxicity assays (EC50 61–100 µg/mL range across four cell lines) and ex vivo cardiac tissue preparations, which provide mechanistic hypotheses but cannot be extrapolated to human efficacy or safety. The narrow apparent therapeutic window suggested by in vitro data—with cytostatic effects at 12.5 µg/mL and near-complete cytotoxicity at 200 µg/mL—combined with the potent cardiac glycoside content, indicates that bridging studies including pharmacokinetic profiling, maximum tolerated dose determination in animal models, and toxicological characterization are prerequisites before any human research could ethically proceed. Confidence in clinical benefit is currently absent, and the ingredient must be classified as research-stage only.

Nutritional Profile

Antiaris toxicaria is not a nutritional food ingredient and has not been characterized for macronutrient or micronutrient content in any published dietary analysis. Proximate analysis of leaf material has identified approximately 7.7% moisture content and 2.2% total ash, indicating a modest mineral content, though specific mineral identities and concentrations have not been reported. The phytochemical profile includes cardiac glycosides (antiarosides A–I, antiarotoxinin A, malayoside) in bark; hydroxycinnamate derivatives (compounds 2–10, 15–16) as major components in leaves; a rutin isomer (flavonoid, compound 12); and additional secondary metabolites including tannins, saponins, alkaloids, and sterols detected across 10 of 17 phytochemical groups screened. No data on lipid, protein, carbohydrate, fiber, vitamin, or specific mineral concentrations are available; bioavailability of any constituent following oral ingestion in humans has not been studied, and the cardiac glycoside content renders meaningful nutritional use impossible without extensive safety characterization.

Preparation & Dosage

- **Traditional Seed Preparation (Papua New Guinean, Siwai/Buin)**: Seeds are heated and administered orally for the treatment of small skin growths; no quantified dose, frequency, or duration of treatment is documented in available ethnobotanical literature.
- **Hydro-alcoholic/Aqueous Leaf Extract**: Used in in vitro research at concentrations of 12.5–200 µg/mL; no human-equivalent dose has been established or can be safely extrapolated.
- **Methanolic Leaf Extract**: Demonstrated antioxidant activity in DPPH assays; extraction yield and phytochemical potency vary by solvent polarity, with methanol producing higher antioxidant activity than petroleum ether (0.89%) or chloroform (2.91%) fractions.
- **Ethanolic Bark Extract**: Used in ex vivo cardiotonic studies; concentration not standardized; no commercial formulation exists.
- **Hexane and Dichloromethane (DCM) Extracts**: Employed in phytochemical screening only; not suitable for oral use without extensive safety validation.
- **Supplemental Use**: No established supplemental dose, standardization percentage, or commercially available form exists; use outside of controlled research settings is not recommended due to cardiac glycoside cardiotoxicity risk.

Synergy & Pairings

No evidence-based synergistic ingredient combinations have been studied or reported for Antiaris toxicaria in any preclinical or clinical context. By phytochemical analogy, the rutin isomer content may theoretically complement quercetin or hesperidin co-administration for additive antioxidant and vascular effects, given the established bromelain-rutin synergy for flavonoid bioavailability enhancement, but this is entirely speculative in the context of this species. Any exploration of combination use is premature and potentially dangerous given the uncharacterized cardiac glycoside content, and no named therapeutic stacks or formulations involving Antiaris toxicaria are commercially recognized or scientifically validated.

Safety & Interactions

Antiaris toxicaria carries a high toxicity risk profile driven primarily by its cardiac glycoside content (antiarosides, antiarotoxinin A, malayoside), which inhibit Na⁺/K⁺-ATPase and can cause life-threatening cardiac arrhythmias, heart block, and ventricular fibrillation at doses that exceed an extremely narrow therapeutic window, analogous to the well-documented toxidrome of ouabain and digitalis glycosides. Specific drug interactions have not been clinically characterized for this species, but by mechanism, co-administration with other cardiac glycosides (e.g., digoxin), antiarrhythmics (e.g., amiodarone, quinidine), calcium channel blockers, or drugs affecting potassium homeostasis (loop diuretics, thiazides) would be expected to dramatically potentiate cardiotoxic risk. No safe dose has been established in humans, no maximum tolerated dose data in animals have been published, and in vitro cytotoxicity at 50–200 µg/mL underscores a narrow margin between biological activity and cellular lethality. This ingredient is absolutely contraindicated in pregnancy, lactation, pediatric populations, and any individual with cardiac disease, electrolyte disorders, or renal impairment; it should not be self-administered or consumed outside of strictly controlled investigational settings.